Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
1.760
+0.030 (1.73%)
Jun 14, 2024, 11:48 AM EDT - Market open

Company Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.

The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.

It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system.

It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions.

The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally.

The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.

Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Virax Biolabs Group Limited
Virax Biolabs Group logo
Country United Kingdom
Founded 2013
IPO Date Jul 21, 2022
Industry Biotechnology
Sector Healthcare
Employees 11
CEO James Foster

Contact Details

Address:
Biocity Glasgow, Bo'ness Road, Newhouse
Lanarkshire, X0 ML1 5UH
United Kingdom
Phone 44 020 7788 7414
Website viraxbiolabs.com

Stock Details

Ticker Symbol VRAX
Exchange NASDAQ
Fiscal Year April - March
Reporting Currency USD
IPO Price $5.00
CIK Code 0001885827
CUSIP Number G9495L109
ISIN Number KYG9495L1251
SIC Code 2835

Key Executives

Name Position
James Foster Chairman and Chief Executive Officer
Jason D. Davis Chief Financial Officer
Mark James Ternouth Chief Technical Officer and Director
Dr. Tomasz Evan George Chief Scientific Officer
Dr. Nigel McCracken M.Sc., Ph.D. Chief Operating Officer
Joel Yeung Accounting Manager
Clement Monteil Head of Scientific Research and Development
James Wang Head of Procurement and Sourcing
Lily Fu Head of Supply Chain

Latest SEC Filings

Date Type Title
Jun 11, 2024 6-K Report of foreign issuer
Apr 25, 2024 6-K Report of foreign issuer
Apr 16, 2024 6-K Report of foreign issuer
Mar 15, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 22, 2024 6-K Report of foreign issuer
Jan 22, 2024 424B5 Filing
Jan 12, 2024 6-K Report of foreign issuer
Dec 21, 2023 6-K Report of foreign issuer
Dec 20, 2023 424B3 Prospectus